کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2126192 1547277 2006 14 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
What clinicians need to know about antioestrogen resistance in breast cancer therapy
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
What clinicians need to know about antioestrogen resistance in breast cancer therapy
چکیده انگلیسی

Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positive patients. Unfortunately, despite high ER tumour levels in a tumour, resistance to endocrine therapy, either de novo or acquired after prolonged treatment, can occur. In this review, we will try to summarise the postulated mechanisms of hormonal-resistance, namely, the role of co-regulators and the crosstalk between the HER-2, IGF-IR, Cox-2 and ER pathways. Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 42, Issue 16, November 2006, Pages 2692–2705
نویسندگان
, , , , ,